儿童再生障碍性贫血:一线与IST失败后移植结局相当
该研究纳入179例儿童重型再生障碍性贫血患者,其中87例接受一线造血干细胞移植,92例在免疫抑制治疗失败后接受移植。中位随访4.0年,5年总生存率89%,无GVHD无复发生存率79%。一线移植总生存率优于IST失败后移植(95% vs 83%,P<.01),但2015年后两者总生存率相当(97% vs 89%,P=.09)。
要点
- 一线MSD或≥9/10 MUD移植的儿童SAA患者总生存率均达95%。
- 2015年后,一线移植与IST失败后移植的总生存率无显著差异。
- MUD移植中,一线与IST失败后移植的GRFS无差异(77% vs 76%)。
核心结论
- 儿童SAA移植结局良好,一线移植与IST失败后移植的长期生存结局在近年已趋于相当。
研究设计与样本
- 回顾性队列研究,纳入179例儿童重型再生障碍性贫血患者,87例接受一线HSCT,92例接受IST失败后HSCT。
主要发现
- 中位随访4.0年(范围0.2-10.7),161例存活。
- 移植失败累积发生率10%,2-4级急性GVHD为18%,慢性GVHD为8%。
- 5年总生存率为89%,无GVHD无复发生存率为79%。
- 一线MSD或≥9/10 MUD移植的总生存率均为95%。
- 一线移植总生存率优于IST失败后移植(95% [95% CI, 89-100] vs 83% [95% CI, 75-91];P<.01)。
关键数值与推荐
- 2015年后,一线移植与IST失败后移植的总生存率分别为97%和89%(P=.09)。
- MUD移植中,一线与IST失败后移植的GRFS分别为77%和76%(P值无显著性差异)。
临床怎么用
- 无MSD时,可获取的MUD一线移植是可行选择;IST失败后采用良好匹配的无关供者移植也可获得良好结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We investigated the outcomes of 179 pediatric patients with severe aplastic anemia (SAA) who received up-front hematopoietic stem cell transplantation (HSCT; n = 87) or received HSCT after failure of immunosuppressive therapy (IST; n = 92). With a median follow-up of 4.0 years (range, 0.2-10.7) after HSCT, 161 patients were alive at last follow-up. The cumulative incidence of graft failure, grade 2 to 4 acute and chronic graft-versus-host disease (GVHD) was 10%, 18%, and 8%, respectively. Five-year overall survival (OS) and GVHD-free, relapse/rejection-free survival (GRFS) were 89% and 79%, respectively. Patients who received up-front HSCT from a matched sibling donor (MSD) or ≥9/10 HLA-matched unrelated donor (MUD) both achieved an OS of 95%. OS was superior in patients who received up-front HSCT than those who received HSCT after failure of IST (up-front, 95% [95% CI, 89-100] vs after IST failure, 83% [95% CI,75-91]; P < .01). However, OS in the HSCT group after IST failure improved over time, resulting in comparable OS between up-front HSCT and HSCT after IST failure from 2015 (97% vs 89%; P = .09). Moreover, there was no difference in GRFS of MUD-HSCT comparing patients who received a transplant up front or after IST failure (up-front, 77% vs after IST failure, 76%; P value not significant). Our data highlight the good transplant outcomes of a consecutive pediatric SAA cohort. Although up-front HSCT from a readily available MUD is a viable option if an MSD is not available, HSCT after IST failure from a well-matched unrelated donor also yields favorable outcomes.
引用
- Andresen F, Yoshimi A, Bader P, et al. Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years. Blood Adv. 2026. PMID: 41558034. doi:10.1182/bloodadvances.2025018285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。